Benefits
Improved glucose tolerance in metabolic syndrome
In BMI>=23 subjects, 10 g/day trehalose vs sucrose significantly decreased post-OGTT glucose at 2 hours vs baseline. In stratified analysis of those with higher truncal fat percentage, body weight, waist circumference, and systolic BP all improved more in the trehalose group. First evidence trehalose may slow progression of insulin resistance in humans.
Maintained glucose homeostasis at low dose in healthy adults
In healthy adults, 3.3 g/day trehalose maintained 2-hour post-OGTT glucose unchanged from fasting (no excursion), while the sucrose group showed expected post-glucose-load elevation. Effect was strongest in the subset with higher baseline 2-h PG/FPG ratios. Suggests even low-dose trehalose may reduce postprandial glycemic excursion in healthy individuals.
Autophagy induction (mechanism with therapeutic implications)
Trehalose is an mTOR-independent autophagy inducer — activates TFEB and FOXO1 transcription factors driving lysosomal biogenesis and autophagy genes. In animal models, this clears mutant huntingtin, alpha-synuclein, and TDP-43 aggregates. Multiple ongoing human trials for ALS, Parkinson's, and Spinocerebellar Ataxia Type 3 are testing whether this preclinical mechanism translates to clinical benefit.
Lower glycemic and insulinemic response than sucrose
Trehalose's α-1,1 bond produces slower digestion than sucrose's α-1,2 bond, resulting in attenuated postprandial glucose, insulin, and GIP responses. Although it is fully digested to glucose, the slower release rate may have favorable downstream effects on adipogenesis and insulin sensitivity vs. an equivalent sucrose intake.
Mechanism of action
Autophagy induction via TFEB/FOXO1 (the dominant therapeutic mechanism)
Trehalose activates the master transcription factor TFEB (transcription factor EB) and FOXO1, both of which drive transcription of autophagy and lysosomal biogenesis genes. This produces: (a) clearance of misfolded protein aggregates relevant to neurodegeneration, (b) reversal of cardiometabolic dysfunction in diet-induced atherosclerosis/steatosis models, and (c) anti-inflammatory effects via macrophage autophagy. The mechanism is mTOR-independent — distinguishing trehalose from rapamycin and explaining its lack of immunosuppressive effects.
Protein structural stabilization via vitrification
Trehalose forms a glassy, anhydrous matrix around proteins that prevents denaturation under stress (heat, freeze, oxidation, dehydration) — basis for its industrial use in vaccine and biologic stabilization. In neurodegenerative contexts, this may also protect against protein misfolding and aggregation, an effect distinct from autophagy induction.
Slower digestion via α-1,1 glycosidic bond
Trehalose is hydrolyzed by intestinal trehalase (rather than amylase or sucrase-isomaltase). The α-1,1 bond is more thermostable and has slower enzymatic cleavage than α-1,2 (sucrose) or α-1,4 (maltose). This explains the lower glycemic index (GI ~70 in pure trehalose vs ~92 for maltose, ~65 for sucrose) and attenuated insulin/GIP response.
Nrf2-mediated antioxidant response
Trehalose increases p62/SQSTM1 expression, leading to enhanced nuclear translocation of Nrf2 and induction of antioxidant response element (are) gene products including heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1). This represents a fourth mechanism contributing to cellular protection beyond autophagy induction alone.
Clinical trials
Placebo-controlled, double-blind clinical trial (Mizote A, Yamada M, Yoshizane C, Arai N, Maruta K, Arai S, Endo S, Ogawa R, Mitsuzumi H, Ariyasu T, J Nutr Sci Vitaminol 62(6):380-387, doi:10.3177/jnsv.62.380).
34 subjects with BMI ≥23 (metabolic syndrome risk factors). Divided into two groups; assigned to ingest 10 g/day trehalose or sucrose (control) with meals for 12 weeks. Body composition and biochemistry measured at 0, 8, 12 weeks; washout at 16 weeks.
Trehalose group: blood glucose 2-h post-OGTT significantly decreased after 12 weeks vs baseline (sucrose group did not change significantly). In stratified analysis of subjects with truncal fat percentage near upper end of normal: body weight, waist circumference, and systolic BP changes were significantly more favorable in trehalose vs sucrose group. Concluded daily 10 g trehalose improved glucose tolerance and slowed progression toward insulin resistance.
Randomized, double-blind, placebo-controlled trial (Yoshizane C, Mizote A, Arai C, Arai N, Ogawa R, Endo S, Mitsuzumi H, Nutr J 19(1):68, doi:10.1186/s12937-020-00586-0).
50 healthy Japanese adults randomized to 3.3 g/day trehalose (n=25) or sucrose (n=25) for 78 days (12 weeks). 75-g oral glucose tolerance tests at baseline and 12 weeks.
Sucrose group: 2-h plasma glucose significantly higher than fasting after 12 weeks. Trehalose group: 2-h and fasting plasma glucose remained similar (no postprandial elevation). In subset with above-mean baseline 2-h PG/FPG ratio, trehalose group's 2-h PG was significantly lower than sucrose group's. Established that low-dose (one teaspoon) trehalose may help maintain glucose homeostasis in healthy individuals.
Acute crossover comparison (Yoshizane C, Mizote A, Yamada M, Arai N, Arai S, Maruta K, Mitsuzumi H, Ariyasu T, Endo S, Nutr J 16(1):9, doi:10.1186/s12937-017-0233-x).
Healthy adults receiving acute oral trehalose vs other sugars with measurement of glycemic, insulinemic, and incretin (GIP, GLP-1) responses.
Trehalose produced significantly lower postprandial glucose, insulin, and GIP responses compared to equivalent sucrose or maltose loads. GLP-1 was preserved or enhanced. Mechanistic foundation for the longer-term metabolic benefits observed in and — slower digestion translates to attenuated metabolic excursion.